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Abstract (250/250 words) 126 
Purpose: Tissue factor (TF) is a potential target in cervical cancer as it is frequently 127 
highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class 128 
investigational antibody-drug conjugate targeting TF, has demonstrated encouraging 129 
activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 130 
201 phase 1/2 study (NCT02001623). 131 
Experimental Design: Patients with recurrent or metastatic cervical cancer received 132 
tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable 133 
toxicity, or consent withdrawal. The primary objective was safety and tolerability. 134 
Secondary objectives included antitumor activity.  135 
Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the 136 
recurrent or metastatic setting; 67% had prior bevacizumab+doublet chemotherapy. 137 
51% of patients had squamous cell carcinoma. The most common grade 3/4 treatment-138 
emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). 139 
No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective 140 
response rate (ORR) was 24% (95% confidence interval [CI]: 13%−37%). Median 141 
duration of response (DOR) was 4.2 months (range: 1.0+−9.7); four patients responded 142 
for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 143 
17%−43%). Independent review outcomes were comparable, with confirmed ORR of 144 
22% (95% CI: 12%−35%), median DOR of 6.0 months (range: 1.0+−9.7), and 6-month 145 
PFS rate of 40% (95% CI: 24%−55%). TF expression was confirmed in most patients; 146 
no significant association with response was observed. 147 
8 
Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and 148 
encouraging antitumor activity in patients with previously treated recurrent or metastatic 149 
cervical cancer.  150 
9 
Translational Relevance (149/150 words) 151 
Treatment of recurrent or metastatic cervical cancer upon disease progression on or 152 
after first-line therapy is variable, and current treatment options provide minimal benefit 153 
with no current second-line standard of care. Tissue factor is aberrantly expressed in 154 
cervical cancer and is associated with poor prognosis, making it a potential therapeutic 155 
target. In this final analysis of the full cervical cancer cohort from the innovaTV 201 156 
study (N = 55), tisotumab vedotin showed a manageable safety profile and encouraging 157 
antitumor activity in this advanced, previously treated cervical cancer population. 158 
Responses with tisotumab vedotin were observed across histological types and prior 159 
treatment type received, including bevacizumab in combination with doublet 160 
chemotherapy. This study provides evidence to support the continued investigation of 161 
tisotumab vedotin as a potential treatment option for the cervical cancer patient 162 
population that currently lacks effective therapies, has high risk of relapse, and has low 163 
survival after first-line treatment.   164 
10 
Introduction 165 
Cervical cancer is a common cancer in women, with an estimated 570,000 new cases 166 
globally in 2018, and represents the third-leading cause of cancer-related death in 167 
women worldwide (1). Approximately 15,500 and 61,000 new cases of cervical cancer 168 
were estimated in North America and in Europe in 2018, respectively, resulting in 169 
approximately 5,800 and 25,800 deaths (2). Recurrent or metastatic cervical cancer has 170 
a poor prognosis, with a 5-year survival rate of 17% (3). Bevacizumab and doublet 171 
chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) was adopted as 172 
first-line (1L) standard-of-care therapy for recurrent or metastatic cervical cancer in the 173 
past 5 years (4-6). However, nearly all patients relapse after 1L treatment, and single-174 
institution experiences indicate that the percentage of patients who receive a second-175 
line (2L) therapy varies (30%–70%) as many patients die before receiving treatment 176 
(7,8).  177 
 178 
Available 2L+ therapies for recurrent or metastatic cervical cancer are characterized by 179 
low response rates (5,6). Before adoption of bevacizumab plus doublet chemotherapy in 180 
1L, therapies administered in the 2L+ setting reported response rates in the range of 181 
4.5–15%, with median survival <8 months (9-15). Data in the post-bevacizumab plus 182 
chemotherapy setting are limited, with a single-institution study showing single-digit 183 
response rates (0%–6%) for 2L treatment (7), suggesting prior vascular endothelial 184 
growth factor inhibition may negatively impact subsequent treatment response. Data in 185 
the third-line setting are further limited, with approximately 60% of patients not receiving 186 
third-line treatment and, when treated, response rates of 3% (8). Recently, 187 
11 
pembrolizumab (anti–programmed death 1) was granted accelerated approval in the 188 
United States for the 2L+ treatment of patients with programmed death-ligand 1 (PD-189 
L1)-positive (combined positive score ≥1%) recurrent or metastatic cervical cancer (16). 190 
However, only a fraction of these patients respond (objective response rate [ORR]: 191 
14%) (16). In addition, efficacy in nonsquamous recurrent or metastatic cervical cancer 192 
is not yet known as 92% of the patients studied had squamous histology (16). These 193 
data underscore the high and immediate need for effective therapies that provide 194 
clinical benefit in a broader patient population. 195 
 196 
Tisotumab vedotin is a first-in-class investigational antibody-drug conjugate (ADC) 197 
comprising a tissue factor (TF)-specific, fully human monoclonal antibody conjugated to 198 
the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) 199 
using a protease-cleavable linker (17,18). Under normal physiological conditions, TF is 200 
central to the coagulation pathway (19). In oncogenesis, TF plays a role in tumor-201 
associated angiogenesis, progression, and metastasis (20-23). TF is aberrantly 202 
expressed across many solid tumors, including cervical cancer (20,24-26), and has 203 
been associated with poor clinical outcomes (20). The expression of TF across tumor 204 
types and its role in oncogenesis make it an appealing therapeutic target. 205 
 206 
Tisotumab vedotin delivers MMAE to TF-expressing cells to induce direct cytotoxicity 207 
and bystander killing of neighboring cells (17,18). In vitro studies demonstrated that 208 
tisotumab vedotin induces immunogenic cell death and efficiently engages with immune 209 
cells to promote tumor cell death through Fcγ receptor–mediated effector functions, 210 
12 
such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular 211 
phagocytosis (18,27). Moreover, tisotumab vedotin was found to inhibit TF-activated 212 
factor VII (FVIIa)–dependent intracellular signaling while minimally impacting 213 
procoagulant activity (18). To our knowledge, tisotumab vedotin is the first drug to 214 
successfully target TF. 215 
 216 
innovaTV 201 (NCT02001623) is a phase 1/2 dose-escalation and expansion trial 217 
evaluating tisotumab vedotin in patients with previously treated locally advanced or 218 
metastatic solid tumors. In the dose-escalation phase, tisotumab vedotin showed a 219 
manageable safety profile, and 2.0 mg/kg every 3 weeks was established as the 220 
recommended phase 2 dose (28). Here, we report the safety and antitumor activity of 221 
tisotumab vedotin in the cervical cancer expansion cohort. 222 
 223 
Methods 224 
Study Oversight 225 
Genmab A/S sponsored the study, provided study drug, and collaborated with academic 226 
investigators on study design, data analysis/interpretation, and manuscript writing. The 227 
trial was conducted in accordance with the International Conference on Harmonization 228 
Good Clinical Practice Guidelines, Declaration of Helsinki, and all applicable regulatory 229 
requirements. The trial protocol was approved by an independent ethics committee or 230 
institutional review board prior to initiation. All patients gave written informed consent. 231 
All authors confirm the accuracy of the data and adherence of the trial to the protocol. 232 
 233 
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Study Design and Patients 234 
innovaTV 201 is an open-label, multi-cohort, phase 1/2 dose escalation and expansion 235 
study of tisotumab vedotin for the treatment of locally advanced and/or metastatic solid 236 
tumors known to express TF.  237 
 238 
The dose escalation phase of the innovaTV 201 study followed a standard 3+3 design 239 
to evaluate tisotumab vedotin at doses of 0.3 mg/kg up to 2.2 mg/kg administered 240 
intravenously every 3 weeks. The dose of tisotumab vedotin used in the expansion 241 
cohort was based on the safety and efficacy data from the dose escalation phase (28). 242 
The expansion phase included patients with locally advanced and/or metastatic cervical, 243 
ovarian, prostate, bladder, esophageal, endometrial, and non–small cell lung cancer 244 
who have progressed on or are ineligible for standard treatments (28). The cervical and 245 
ovarian cancer cohorts were expanded from the initial 14 patients to approximately 30 246 
patients each based on preliminary clinical activity and safety observed. After an 247 
amendment to the protocol, up to an additional 25 patients could be enrolled in the 248 
cervical cancer cohort for a maximum of 55 patients in total.  249 
 250 
Eligible patients had measurable disease per Response Evaluation Criteria In Solid 251 
Tumors (RECIST) v1.1 and an Eastern Cooperative Oncology Group (ECOG) 252 
performance status of 0 or 1. Patients with known coagulation defects, ongoing major 253 
bleeding, or Common Toxicity Criteria for Adverse Events (CTCAE) grade ≥2 254 
neuropathy were excluded. A protocol amendment allowed for enrollment of patients on 255 
anticoagulants. Patients in the cervical cancer cohort had recurrent/metastatic disease, 256 
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progressed on a platinum-based regimen, and received ≤4 prior treatments for 257 
advanced disease.  258 
 259 
Treatment and Assessments 260 
Patients in the cervical cancer cohort received tisotumab vedotin 2.0 mg/kg intravenous 261 
infusion every 3 weeks for four cycles. Patients with clinical benefit (stable disease or 262 
better) at the end of four cycles had the option to continue treatment for an additional 263 
eight cycles (up to 12 cycles total), or until disease progression or unacceptable toxicity. 264 
After 12 cycles, patients with clinical benefit could continue in an extension study 265 
(NCT03245736).  266 
 267 
Safety was monitored throughout the study and for up to 30 days after the last dose. 268 
Adverse events (AEs) were graded according to the National Cancer Institute CTCAE 269 
v4.03 and coded according to Medical Dictionary for Regulatory Activities (MedDRA) 270 
v17.0. AEs of special interest (AESIs) were identified during the dose escalation phase 271 
of the study and for which pooled standardized MedDRA queries were applied included 272 
neuropathies (known MMAE-related AEs), bleeding-related events (because of TF’s 273 
role in coagulation), and ocular events (conjunctivitis, conjunctival ulceration, keratitis, 274 
symblepharon).  275 
 276 
Protocol amendments implementing additional exclusion criteria and mitigation 277 
measures to reduce the risk for ocular events were introduced throughout the study. 278 
Patients with active ocular surface disease at baseline or a history of cicatricial 279 
15 
conjunctivitis were excluded. Mitigation strategies included the application of 280 
preservative-free lubricating eye drops from the start of study treatment until the end of 281 
treatment, administration of local ocular vasoconstrictor eye drops immediately prior to 282 
the start of infusion, cooling eye pads worn during infusion, and application of steroid 283 
eye drops for 3 days beginning on the day of infusion. Furthermore, the use of contact 284 
lenses was avoided, and stricter dose modification guidance for ocular events was 285 
provided. 286 
 287 
Tumor responses were assessed by investigator and independent review committee 288 
(IRC) using magnetic resonance imaging or computed tomography scans at baseline 289 
and every 6 weeks during the study. Responses were confirmed by subsequent repeat 290 
imaging performed ≥4 weeks after initial response. 291 
 292 
Tumor biopsies were requested upon enrollment in the study. Fresh biopsies were 293 
requested, but the most recent archived sample could be used. If no archived biopsies 294 
were available, a fresh biopsy was taken prior to dosing. Biopsy samples were 295 
retrospectively assessed for membrane and cytoplasmic TF tumor expression in a 296 
central laboratory using an analytically validated immunohistochemistry assay. TF 297 
histology-score (H-score) was calculated based on the percentage of tumor tissue that 298 
had membrane or cytoplasmic TF expression intensity of low (1+), intermediate (2+), 299 
and high (3+) on evaluable samples using the following equation: H-score = (1×[% cells 300 
1+]) + (2×[% cells 2+]) + (3×[% cells 3+]). 301 
 302 
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Study Outcomes 303 
The primary objective of this study was to evaluate the safety and tolerability of 304 
tisotumab vedotin. Key secondary endpoints included ORR (defined as complete 305 
response [CR] or partial response [PR] as assessed by the investigator or IRC), 306 
duration of response (DOR), and progression-free survival (PFS) per RECIST v1.1.  307 
 308 
Statistical Analysis 309 
All patients who received at least one dose of tisotumab vedotin were included in the 310 
safety and antitumor activity analyses. ORR was determined with a corresponding two-311 
sided 95% exact binomial confidence interval (CI). IRC-assessment utilized a 2 readers 312 
plus adjudication method. Agreement between investigator- and IRC-assessment with 313 
respect to confirmed objective response was determined using Cohen’s kappa. Median 314 
PFS and DOR were determined using the Kaplan–Meier method and were presented 315 
with a two-sided 95% CI. Prespecified subgroup factors included TF expression. 316 
Association between TF expression and response was analyzed using analysis of 317 
variance with Tukey’s multi-comparison post hoc test. 318 
 319 
Results 320 
Patients 321 
Between November 2015 and April 2018, 55 patients were enrolled into the cervical 322 
cancer expansion cohort of the innovaTV 201 study (Supplementary Figure S1). The 323 
demographics and baseline disease characteristics are presented in Table 1. Most 324 
patients had ECOG performance status of 1 (73%). Fifty-one percent of the patients had 325 
17 
squamous cell carcinoma and 35% had adenocarcinoma. Fifty-one percent received ≥2 326 
prior lines of treatment. Four patients did not receive 1L standard-of-care therapy 327 
because they were refractory to treatment for early stage disease (concurrent 328 
chemoradiation or neoadjuvant therapy) and were considered as having zero prior lines 329 
of treatment in the recurrent setting. Prior systemic therapies received included taxanes 330 
(91%) and bevacizumab plus doublet chemotherapy (67%). TF expression (≥1%) was 331 
confirmed in the majority of evaluable patients (membrane expression, 100%; 332 
cytoplasmic expression, 95%). 333 
 334 
Safety 335 
At data cutoff (September 30, 2018), the median follow-up was 3.5 months (range: 0.6–336 
11.8). The median number of doses of tisotumab vedotin received was 4.0 (range: 1.0–337 
14.0). Ten patients (18%) discontinued treatment due to an AE, the most common of 338 
which was peripheral neuropathy (9%). Seven patients (13%) had an AE leading to 339 
dose reduction (Supplementary Table S1). 340 
 341 
Treatment-emergent AEs regardless of causality and of any grade were reported in all 342 
patients, and AEs of grade ≥3 were reported in 31 patients (56%) (Table 2). The most 343 
common AEs were epistaxis (51%), fatigue (51%), nausea (49%), conjunctivitis (42%), 344 
and alopecia (40%) (Table 2). Of these, most were grade 1/2. The most common grade 345 
≥3 AEs were anemia (11%), fatigue (9%), and vomiting (7%). Twenty-nine patients 346 
(53%) had serious AEs (Supplementary Table S2), the most common of which were 347 
vomiting (7%) and constipation (5%). Two fatal events occurred while on treatment, 348 
18 
both due to disease progression, and were assessed as unrelated to treatment by 349 
investigator and study sponsor. No treatment-related deaths were observed. 350 
 351 
No grade ≥4 AESIs were observed. Neuropathy AESIs occurred in 30 patients (55%); 352 
six of the AESIs (11%) were grade 3, and the most common was peripheral neuropathy 353 
(all grades: 36%; grade 3: 4%) (Table 2, additional information on neuropathy AESIs is 354 
summarized in Supplementary Table S3). Seventeen patients (31%) had neuropathy 355 
at baseline. Bleeding-related AESIs occurred in 40 patients (73%) and most were grade 356 
1/2, with three patients (5%) experiencing a grade 3 bleeding-related event (two with 357 
vaginal hemorrhage and one with hematuria) (Table 2, additional information on 358 
bleeding-related AESIs is summarized in Supplementary Table S4). The most 359 
common bleeding-related event was epistaxis (51%); all were grade 1 except for one 360 
grade 2. Ocular AESIs of any type occurred in 36 patients (65%), and the most common 361 
were conjunctivitis (42%) and dry eye (24%) (Table 2, additional information on ocular 362 
AESIs is summarized in Supplementary Table S5). The incidence of ocular events was 363 
reduced from 80% in patients enrolled prior to the implementation of mitigation 364 
measures (n = 15) to 60% in patients enrolled after implementation (n = 40). The rates 365 
of conjunctivitis were reduced from 80% to 28% (Figure 1). 366 
 367 
Antitumor Activity 368 
The investigator-assessed confirmed ORR was 24% (95% CI: 13%−37%) (Table 3). 369 
Maximum changes in target lesion size from baseline are shown in Figure 2A. The 370 
median time to response was 2.6 months (range: 1.1−3.9) and the median DOR was 371 
19 
4.2 months (range: 1.0+−9.7) (Table 3). Four patients experienced a confirmed PR for 372 
≥8 months (Figure 2B). The median PFS was 4.2 months (95% CI: 2.1−5.3), and the 6-373 
month PFS rate was 29% (95% CI: 17%−43%) (Table 3, Supplementary Figure S2).  374 
 375 
The IRC-assessed confirmed ORR was 22% (95% CI: 12%−35%) (Table 3), which 376 
included one patient who had a CR by IRC-assessment. Four patients were refractory 377 
to prior treatment for early stage disease and did not receive standard of care (doublet 378 
chemotherapy ± bevacizumab) for first-line treatment of recurrent or metastatic disease. 379 
In these patients (n = 51), the IRC-assessed confirmed ORR was 24% (95% CI: 13%–380 
38%). The overall agreement between investigator- and IRC-assessment with respect 381 
to ORR was 95% (Cohen’s kappa 0.84). The median IRC-assessed DOR was 6.0 382 
months (range: 1.0+−9.7), and the 6-month PFS rate was 40% (95% CI: 24%−55%) 383 
(Table 3, Supplementary Figure S3). 384 
 385 
Figure 2C shows the target and non-target lesion baseline and follow-up scans of a 43-386 
year-old female patient with squamous cell carcinoma previously treated with paclitaxel 387 
plus carboplatin. This patient achieved PR after 16 weeks of treatment and discontinued 388 
tisotumab vedotin due to an AE at that time. The decreased target lesion size persisted 389 
after treatment discontinuation up to week 47. 390 
 391 
Subgroup and Biomarker Analysis 392 
Investigator-assessed responses with tisotumab vedotin were observed across 393 
histologic types (squamous cell carcinoma ORR, 29% [8/28 patients]; adenocarcinoma 394 
20 
ORR, 16% [3/19]) and for patients who received zero (25% [1/4]), one (22% [5/23]), two 395 
(35% [6/17]), or 3–4 (9% [1/11]) prior lines of therapy (Figure 3A). Patients who 396 
previously received bevacizumab plus doublet chemotherapy demonstrated a similar 397 
ORR to the overall population (22% [8/37]).  398 
 399 
TF expression in relation to clinical response was evaluable in tissue samples from 44 400 
of the 55 patients (80%), as three patients had no biopsy, four were not evaluable for 401 
response by RECIST v1.1, and five had insufficient tumor material (one patient not 402 
evaluable for response also had insufficient tumor material). Of the evaluable cases, 37 403 
patients (84%) had archival biopsies and seven (16%) had fresh biopsies. Seventeen of 404 
the 37 patients (46%) with archived tissue had no prior treatment at the time of biopsy. 405 
There was no statistically significant difference in TF expression between biopsy 406 
samples taken with no prior treatment compared to recurrent cervical cancer biopsy 407 
samples (data not shown). Twenty-seven biopsies (61%) were from primary tumors and 408 
17 (39%) were from metastatic lesions. Membrane and cytoplasmic TF expression (H-409 
score) were comparable across histological types (Figure 3B-C). Investigation of 410 
membrane or cytoplasmic TF expression did not show a statistically significant 411 
association with investigator-assessed best overall confirmed response (Figure 3D-E). 412 
 413 
Discussion 414 
In patients with advanced recurrent or metastatic cervical cancer, tisotumab vedotin, a 415 
first-in-class ADC designed to target TF, demonstrated a manageable safety profile and 416 
encouraging antitumor activity in a patient population for which no standard-of-care 417 
21 
therapy exists. To our knowledge, tisotumab vedotin is the first ADC to successfully 418 
demonstrate meaningful clinical activity specifically targeting TF, a novel target 419 
overexpressed in many solid tumors associated with poor outcomes. 420 
 421 
The safety profile of tisotumab vedotin was generally consistent with other MMAE-422 
based ADCs, except for epistaxis and conjunctivitis (29,30). Almost all epistaxis events 423 
were grade 1, and none required clinical intervention. Moreover, as TF is highly 424 
expressed in the nasal epithelium (31), this observation may reflect a local disruption of 425 
the nasal mucosa rather than an underlying treatment-induced coagulopathy. The 426 
incidence of other bleeding-related events was consistent with the expected incidence 427 
observed in patients with advanced cervical cancer. Most ocular events were grade 1/2, 428 
except for one patient with grade 3 conjunctivitis. The incidence of ocular events, 429 
including conjunctivitis, was reduced in the patients enrolled after implementation of 430 
mitigation measures. Although the mechanism of the ocular events is not known, TF 431 
expression has been demonstrated in the ocular epithelium (32,33), which may result in 432 
treatment-emergent toxicity in these cells. The understanding of TF-related epistaxis 433 
and ocular events is continuing to evolve, and further studies are needed to optimize 434 
mitigation strategies, as well as to assess the long-term effects of tisotumab vedotin, the 435 
duration of these AESIs, and the mechanisms by which they occur. 436 
 437 
The ORR observed with tisotumab vedotin across histologies, line of therapy, and prior 438 
treatments, including bevacizumab plus doublet chemotherapy, is clinically important in 439 
a patient population that lacks effective therapies. Tisotumab vedotin demonstrated a 440 
22 
notable response rate (24% by investigator assessment) and meaningful 6-month PFS 441 
rate in this previously treated patient population with advanced cervical cancer, 442 
including in patients with adenocarcinoma histology. In contrast, an ORR of 14% was 443 
observed in patients with PD-L1−positive cervical cancer treated with pembrolizumab 444 
(16). The efficacy of pembrolizumab in patients with nonsquamous histology has not 445 
been well established as the majority of patients (92%) enrolled in the clinical trial of 446 
pembrolizumab had squamous cell carcinoma (16), and although the median DOR was 447 
not reached, meaningful PFS benefit was not observed (34).  448 
 449 
The antitumor activity of tisotumab vedotin is further supported by the concordance 450 
between the investigator- and IRC-assessed ORR and prolonged responses. The 451 
durability of response with tisotumab vedotin is highlighted by the four patients with 452 
response >8 months and the patient case demonstrating persistent PR despite 453 
tisotumab vedotin discontinuation. The durable responses observed may be indicative 454 
of the multiple proposed mechanisms of action of tisotumab vedotin, including direct 455 
cytotoxicity, bystander killing, and immunogenic cell death induced by MMAE, as well as 456 
Fcγ receptor–mediated effector functions and inhibition of TF/FVIIa signaling (17,18,27).  457 
 458 
The majority of cervical cancer patient biopsies had detectable TF expression. Both 459 
membrane and cytoplasmic levels of TF expression were comparable across various 460 
cervical cancer histological types. Although median membrane and cytoplasmic TF H-461 
score was higher in patients who achieved PR and stable disease compared to those 462 
with progressive disease, there was no statistically significant association with best 463 
23 
confirmed response. That said, the majority of samples were from archival tissue, and 464 
the effect of previous lines of therapy on TF expression has yet to be explored. Further 465 
studies evaluating TF expression and other potential predictive biomarkers that 466 
associate with antitumor activity will be explored to determine whether certain patient 467 
populations may benefit more from tisotumab vedotin.  468 
 469 
This study demonstrated the antitumor activity of tisotumab vedotin in patients with 470 
advanced, previously treated recurrent or metastatic cervical cancer. However, overall 471 
survival was not a specified endpoint, and thus further studies are needed to establish 472 
the impact of tisotumab vedotin on survival in these patients. The ongoing phase 2 473 
innovaTV 204 study (NCT03438396; ENGOT-cx6; GOG-3032) is investigating the 474 
antitumor activity and safety of tisotumab vedotin in approximately 100 patients with 475 
previously treated recurrent or metastatic cervical cancer. Additionally, the phase 1/2 476 
innovaTV 205 study (NCT03786081; ENGOT-cx8; GOG-3024) is investigating the 477 
combination of tisotumab vedotin with pembrolizumab, bevacizumab, or carboplatin in 478 
the 1L and 2L+ settings in patients with recurrent or metastatic cervical cancer. 479 
 480 
Recurrent or metastatic cervical cancer is a serious, life-threatening disease. The lack 481 
of effective treatments, high relapse risk, and low survival after 1L treatment 482 
demonstrate the need for novel, safe, and effective therapies that improve clinical 483 
benefit. The results of this study cohort have demonstrated the manageable safety 484 
profile and encouraging antitumor activity of tisotumab vedotin, supporting the further 485 
24 
clinical development of this first-in-class ADC targeting the novel therapeutic target, TF, 486 
in patients with previously treated recurrent or metastatic cervical cancer.  487 
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TABLES 627 
 628 
Table 1. Baseline demographics and disease characteristics 629 
Characteristic 
Cervical Cancer 
Cohort 
N = 55 
Age, median (range), years 46 (21–73) 
Race, n (%)a  
 White 49 (92) 
 Asian 3 (6) 
 Black or African American 1 (2) 
ECOG performance status, n (%)  
 0  15 (27) 
 1 40 (73) 
Histology, n (%)  
 Squamous cell carcinoma 28 (51) 
 Adenocarcinoma 19 (35) 
 Adenosquamous carcinoma 6 (11) 
 Otherb 2 (4) 
Prior lines of systemic therapies for recurrent/metastatic 
disease, n (%) 
 
 0c 4 (7) 
 1 23 (42) 
 2 17 (31) 
33 
 3 6 (11) 
 4 5 (9) 
Prior systemic therapies received, n (%)  
 Taxane 50 (91) 
 Bevacizumab 40 (73) 
 Bevacizumab plus doublet chemotherapyd 37 (67) 
TF expression positive, n (%)e  
 Membrane 44 (100) 
 Cytoplasm 42 (95) 
ECOG, Eastern Cooperative Oncology Group; TF, tissue factor. 
aTwo patients were missing race information; percentage prevalence was calculated 
out of n = 53 for race. 
bFollowing the data cutoff date, patients with other histology were resolved as having 
adenosquamous (n = 1) and neuroendocrine (n = 1) histology. 
cPatients did not receive standard-of-care therapy in the first-line recurrent setting 
because they were refractory to treatment administered for early-stage disease 
(concurrent chemoradiation therapy or neoadjuvant therapy). 
dDoublet chemotherapy defined as paclitaxel plus cisplatin or paclitaxel plus 
topotecan. 
ePositive TF expression was defined as ≥1%; percentage prevalence was calculated 
out of TF expression evaluable population (n = 44). 
  630 
34 
Table 2. Treatment-emergent adverse events 631 
Incidence, n (%) 
Cervical Cancer Cohort 
N = 55 
All-grade Grade ≥3 
Patients with ≥1 AE 55 (100) 31 (56) 
AEs With ≥20% Incidence All-grade Grade ≥3 
 Epistaxis 28 (51) 0 
 Fatigue 28 (51) 5 (9) 
 Nausea 27 (49) 3 (5) 
 Conjunctivitis 23 (42) 1 (2) 
 Alopecia 22 (40) 0 
 Decreased appetite 21 (38) 0 
 Constipation 20 (36) 1 (2) 
 Peripheral neuropathy 20 (36) 2 (4) 
 Vomiting 19 (35) 4 (7) 
 Diarrhea 16 (29) 1 (2) 
 Abdominal pain 15 (27) 3 (5) 
 Anemia 13 (24) 6 (11) 
 Dry eye 13 (24) 0 
 Hypokalemia 11 (20) 3 (5) 
 Pruritus 11 (20) 0 
 Pyrexia 11 (20) 1 (2) 
 Urinary tract infection 11 (20) 1 (2) 
AESIs With ≥5% Incidence All-grade Grade 3 
35 
  632 
Neuropathy AESIsa 30 (55) 6 (11) 
 Peripheral neuropathy 20 (36) 2 (4) 
 Muscular weakness 4 (7) 0 
 Peripheral sensory neuropathy 4 (7) 0 
Bleeding-related AESIsb 40 (73) 3 (5) 
 Epistaxis 28 (51) 0 
 Vaginal hemorrhage 7 (13) 2 (4) 
 Hematuria 5 (9) 1 (2) 
 Contusion 3 (5) 0 
Ocular AESIsc 36 (65) 1 (2) 
 Conjunctivitis 23 (42) 1 (2) 
 Dry eye 13 (24) 0 
 Ulcerative keratitis 4 (7) 0 
 Blepharitis 3 (5) 0 
 Keratitis 3 (5) 0 
AE, adverse event; AESI, adverse event of special interest; SMQ, standardized 
Medical Dictionary for Regulator Activities queries. 
aDefined as peripheral neuropathy SMQ. 
bDefined as hemorrhage SMQ. 
cDefined as conjunctival disorders SMQ, corneal disorders SMQ, scleral disorders 
SMQ, retinal disorders SMQ, periorbital disorders SMQ, ocular infections SMQ, and 
optic nerve disorders SMQ. 
36 
Table 3. Investigator- and independent review committee–assessed antitumor 633 
activity of tisotumab vedotin  634 
 
Cervical Cancer Cohort 
N = 55 
Antitumor Activity Investigator-assessed IRC-assessed 
ORR (95% CI), %a 24 (13–37) 22 (12–35) 
 CR, n (%) 0 1 (2) 
 PR, n (%) 13 (24) 11 (20) 
 SD, n (%) 21 (38) 19 (35) 
 Non-CR/Non-PD, n (%) 0 2 (4) 
 PD, n (%) 17 (31) 17 (31) 
 Not evaluable, n (%) 4 (7) 5 (9) 
Median TTR (range), months 2.6 (1.1–3.9) 2.1 (1.1–4.6) 
Median DOR (range), months 4.2 (1.0+–9.7) 6.0 (1.0+–9.7) 
Median PFS (95% CI), months 4.2 (2.1–5.3) 4.1 (1.7–6.7) 
 6-month PFS rate, % (95% CI) 29 (17–43) 40 (24–55) 
CI, confidence interval; CR, complete response; DOR, duration of response; IRC, 
independent review committee; ORR, objective response rate; PD, progressive disease; 
PFS, progression-free survival; PR, partial response; SD, stable disease; TTR, time to 
response. 
+Indicates censored value due to ongoing response. 
aConfirmed ORR by Response Evaluation Criteria In Solid Tumors v1.1 criteria. 
 635 
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FIGURE LEGENDS 636 
 637 
Figure 1. Conjunctivitis before and after mitigation measures. The percentage 638 
incidence of conjunctivitis by grade occurring in patients enrolled before and after the 639 
implementation of mitigation measures are shown. aOne patient with grade 3 640 
conjunctivitis after mitigation measures were implemented. No grade 3 events were 641 
observed before mitigation measures were implemented.  642 
 643 
Figure 2. Investigator-assessed antitumor activity of tisotumab vedotin in patients 644 
with cervical cancer. (A) The maximum percentage change from baseline in target 645 
lesion size as assessed by the investigator and colored by best overall response 646 
according to RECIST v1.1. aFour patients did not have postbaseline scans and one 647 
patient did not have postbaseline assessments of sum of target lesions; these patients 648 
were excluded from this analysis. bPatient had lymph node disease and persistent non-649 
target lesions for overall assessment of PR. cPatient had regression of nodal lesions to 650 
<10 mm short axis diameter of their target lesions and persistent non-target lesions, but 651 
was classified as PD due to a new lesion. (B) Investigator-assessed time to response 652 
and duration of response for patients with confirmed PR as measured by RECIST v1.1 653 
(n = 13). (C) Target and non-target lesion scans at baseline and follow-up visits for a 43-654 
year-old female patient with squamous cell carcinoma previously treated with paclitaxel 655 
and carboplatin. Weeks are measured from cycle 1 day 1 of tisotumab vedotin. The 656 
patient achieved a PR and discontinued tisotumab vedotin due to an adverse event at 657 
38 
week 16 (black arrow). PD, progressive disease; PR, partial response; RECIST v1.1, 658 
Response Evaluation Criteria In Solid Tumors v1.1. 659 
 660 
Figure 3. Response across baseline disease characteristic subgroups and by 661 
tissue factor expression. (A) The investigator-assessed confirmed ORR (95% CI) in 662 
patients with squamous cell carcinoma, adenocarcinoma, or adenosquamous 663 
carcinoma; in patients who received 1, 2, or 3-4 prior lines of systemic treatment; and in 664 
patients who received prior taxanes, bevacizumab, or bevacizumab plus doublet 665 
chemotherapy. aInvestigator-assessed confirmed response by RECIST v1.1. bPatients 666 
with other histology (n = 2) did not have confirmed response. cDoublet chemotherapy 667 
defined as paclitaxel plus cisplatin or paclitaxel plus topotecan. Membrane (B) and 668 
cytoplasmic (C) TF expression intensity as measured by H-score, in patients with 669 
adenocarcinoma, adenosquamous carcinoma, squamous carcinoma, or other histology. 670 
Membrane (D) and cytoplasmic (E) TF expression intensity as measured by H-score in 671 
patients who had investigator-assessed best confirmed PR, SD, or PD. P values are for 672 
descriptive purposes only. CI, confidence interval; H, histology; ORR, objective 673 
response rate; PD, progressive disease; PR, partial response; RECIST v1.1, Response 674 
Evaluation Criteria In Solid Tumors v1.1; SD, stable disease; TF, tissue factor. 675 
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